📊 OMER Key Takeaways
Is Omeros Corp. (OMER) a Good Investment?
Omeros Corp exhibits severe financial distress with negative stockholders' equity of -$121.2M, indicating technical insolvency. The company burns -$116.1M in operating cash annually against minimal cash reserves of $9.7M, providing less than one month of operational runway. Operating losses of -$122.8M substantially exceed $79.9M in revenue, reflecting a fundamentally unprofitable business model unsustainable without immediate capital intervention.
Despite ~$80M in revenue, Omeros posts very large operating losses and deeply negative free cash flow, leading to negative equity and weak interest coverage. A small cash balance relative to burn implies a short runway and a high probability of dilutive or costly financing. The improved net loss appears driven by non-operating items rather than sustainable operating performance.
Why Buy Omeros Corp. Stock? OMER Key Strengths
- Revenue generation of $79.9M demonstrates market traction for pharmaceutical products
- Net income improved 97.9% year-over-year, showing trajectory from deeper losses
- Current ratio of 2.76x indicates working capital availability in current assets
- Established revenue base (~$80M) in a typically pre-revenue sector
- Strong current and quick ratios indicating near-term liquidity coverage
- Minimal capital expenditure requirements
OMER Stock Risks: Omeros Corp. Investment Risks
- Negative stockholders' equity of -$121.2M represents technical insolvency with liabilities exceeding all assets
- Operating cash burn of -$116.1M annually against $9.7M cash reserves creates critical liquidity crisis with <1 month runway
- Operating margin of -153.7% with no demonstrated path to profitability given revenue-to-loss magnitude
- Long-term debt of $87.9M compounds financial obligations while company remains technically insolvent
- Severe operating losses and -$116M operating cash outflow indicate unsustainable burn
- Negative stockholders’ equity and -5.7x interest coverage signal solvency risk
- Small cash balance versus burn implies imminent financing need and dilution risk
Key Metrics to Watch
- Quarterly operating cash flow burn rate and cash runway duration
- Revenue growth trajectory required to approach operating breakeven
- Debt refinancing status and any capital raise or financing announcements
- Operating cash flow (burn rate)
- Cash and equivalents (liquidity runway)
Omeros Corp. (OMER) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.76x current ratio provides a solid financial cushion.
OMER Profit Margin, ROE & Profitability Analysis
OMER vs Healthcare Sector: How Omeros Corp. Compares
How Omeros Corp. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Omeros Corp. Stock Overvalued? OMER Valuation Analysis 2026
Based on fundamental analysis, Omeros Corp. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Omeros Corp. Balance Sheet: OMER Debt, Cash & Liquidity
OMER Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Omeros Corp.'s revenue has grown significantly by 169% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.88 indicates the company is currently unprofitable.
OMER Revenue Growth, EPS Growth & YoY Performance
OMER Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2021 | $26.1M | -$22.7M | $-0.36 |
| Q2 2021 | $13.5M | -$28.6M | $-0.46 |
| Q1 2021 | $21.1M | -$29.0M | N/A |
| Q3 2020 | $26.1M | -$14.5M | N/A |
| Q2 2020 | $13.5M | -$14.5M | N/A |
| Q1 2020 | $21.8M | -$24.3M | N/A |
| Q3 2019 | $4.6M | -$14.5M | N/A |
| Q2 2019 | $1.7M | -$14.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Omeros Corp. Dividends, Buybacks & Capital Allocation
OMER SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Omeros Corp. (CIK: 0001285819)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OMER
What is the AI rating for OMER?
Omeros Corp. (OMER) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are OMER's key strengths?
Claude: Revenue generation of $79.9M demonstrates market traction for pharmaceutical products. Net income improved 97.9% year-over-year, showing trajectory from deeper losses. ChatGPT: Established revenue base (~$80M) in a typically pre-revenue sector. Strong current and quick ratios indicating near-term liquidity coverage.
What are the risks of investing in OMER?
Claude: Negative stockholders' equity of -$121.2M represents technical insolvency with liabilities exceeding all assets. Operating cash burn of -$116.1M annually against $9.7M cash reserves creates critical liquidity crisis with <1 month runway. ChatGPT: Severe operating losses and -$116M operating cash outflow indicate unsustainable burn. Negative stockholders’ equity and -5.7x interest coverage signal solvency risk.
What is OMER's revenue and growth?
Omeros Corp. reported revenue of $79.9M.
Does OMER pay dividends?
Omeros Corp. does not currently pay dividends.
Where can I find OMER SEC filings?
Official SEC filings for Omeros Corp. (CIK: 0001285819) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OMER's EPS?
Omeros Corp. has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OMER a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Omeros Corp. has a STRONG SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OMER stock overvalued or undervalued?
Valuation metrics for OMER: ROE of N/A (sector avg: 15%), net margin of -4.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OMER stock in 2026?
Our dual AI analysis gives Omeros Corp. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OMER's free cash flow?
Omeros Corp.'s operating cash flow is $-116.1M, with capital expenditures of $65.0K. FCF margin is -145.4%.
How does OMER compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4.2% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.76 (avg: 2).